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Introduction 
Bullous pemphigoid is an autoimmune blistering 
disorder characterized by antibodies targeting 
hemidesmosomes at the dermal-epidermal 
junction (DEJ). In the acute setting, topical and 
systemic corticosteroids are typically the first-line 
treatments, which allow providers to bridge 
patients to corticosteroid sparing agents such as 
azathioprine, mycophenolate mofetil, or 
methotrexate. Given their low side effect profile, 
anti-inflammatories such as doxycycline and 
nicotinamide are often added to help control 
disease activity and can be effective when utilized 
alone in BP [6-9]. In refractory cases, biologic 
therapies such as rituximab [10-12] and 
omalizumab [13-17] have shown efficacy in a 
small number of cases. Dupilumab is a 
monoclonal antibody targeting IL4Rɑ that 
reduces interleukin 4- and interleukin 13-
mediated signaling [18]. It has been approved for 
the treatment of atopic dermatitis, as well as 
moderate to severe asthma and chronic 
rhinosinusitis with nasal polyposis. In recent 
reports, dupilumab has been successfully used 
off-label to treat a variety of pruritic disorders, 
including chronic spontaneous urticaria [1], anal 
and genital itch [2], allergic contact dermatitis [3], 
and prurigo nodularis [4, 5]. Herein, we report the 
use of dupilumab for BP in an elderly male with 
inadequately controlled pruritus despite 
concurrent topical corticosteroids, low/moderate 
dose systemic corticosteroids, doxycycline, 
nicotinamide, and mycophenolate mofetil. 
Abstract 
Bullous pemphigoid (BP) is an autoimmune 
blistering disorder that predominantly affects the 
elderly. Treatment regimens typically include 
topical and systemic immunosuppressive 
medications. Although effective, systemic 
corticosteroids are sometimes poorly tolerated in 
the elderly patient, contributing to the overall 
morbidity and mortality of BP. Dupilumab is a 
monoclonal antibody targeting interleukin 4 
receptor alpha (IL4Rα), approved for the treatment 
of atopic dermatitis, as well as moderate to severe 
asthma and chronic rhinosinusitis with nasal 
polyposis. In recent reports, dupilumab has been 
successfully used off-label to treat a variety of 
pruritic disorders, including chronic spontaneous 
urticaria [1], anal and genital itch [2], allergic 
contact dermatitis [3], and prurigo nodularis [4, 5]. 
We report here a case of an elderly patient with 
refractory BP whose symptoms of pruritus and 
blistering became well-controlled with the 
addition of dupilumab to the treatment regimen. 
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Case Synopsis 
An 89-year-old man with type 2 diabetes mellitus 
on metformin presented to our clinic with 
urticarial plaques and bullae despite 15 months of 
ongoing treatment with doxycycline 100mg twice 
daily, nicotinamide 500mg twice daily, 
mycophenolate mofetil 1000mg twice daily (peak 
of 1500mg twice daily), and prednisone 10mg 
daily. Prior skin biopsy showed spongiosis with 
focal epidermal vesicle formation and superficial 
dermal perivascular infiltrate containing 
eosinophils and lymphocytes. Direct 
immunofluorescence showed linear IgG and C3 
deposition at the dermal-epidermal junction, 
consistent with the diagnosis of bullous 
pemphigoid. The patient was not on any 
medications suspected to be causing his BP. His 
treatment course was complicated by 
exacerbation of his type 2 diabetes mellitus, 
corticosteroid myopathy, and thrush. Although 
moderate doses of prednisone effectively reduced 
the severity of blistering lesions, his pruritus and 
diabetes were not sufficiently controlled. 
Attempts to very slowly taper his prednisone 
resulted in disease flares and severe pruritus. After 
two years, the patient complained of pill fatigue 
and concerns about prednisone and diabetes, 
thus a trial of omalizumab was initiated as an 
alternative corticosteroid sparing agent. He 
initially responded well, but experienced a disease 
flare 6 months after starting omalizumab. The 
patient elected to discontinue omalizumab owing 
to loss of efficacy. After a period off omalizumab, 
the patient was started on dupilumab. Within two 
weeks of starting dupilumab, the patient’s 
pruritus markedly improved and at his 7-week 
follow up, his BP lesions had completely resolved. 
He is currently taking dupilumab every other 
week, prednisone 2.5mg daily, mycophenolate 
mofetil 500mg twice daily, doxycycline 100mg 
twice daily, and nicotinamide 500mg twice daily; 
he uses topical, clobetasol 0.05% cream as 
needed. Our patient reported complete resolution 
of his pruritus after the first dose of dupilumab 
and continued benefit from the medication at 
one-year follow-up. 
 
Case Discussion 
Dupilumab is a human monoclonal antibody 
targeting IL4Rɑ that inhibits the signaling of Th2 
cytokines, interleukin 4, and interleukin 13. It is 
currently approved for the treatment of atopic 
dermatitis, as well as moderate to severe asthma 
and chronic rhinosinusitis with nasal polyposis. 
Eosinophilic infiltration and production of Th2 
cytokines are critical drivers of these diseases. 
Interestingly, studies have shown that eosinophils 
can contribute to the pathogenesis of BP by 
causing separation of the DEJ and driving anti-
BP180 IgE-mediated skin blistering [19-25]. In 
addition, IL4 is essential for the initial recruitment 
of eosinophils, which promotes a positive 
feedback loop, contributing to further production 
of IL4 [26]. Expression of IL4 and IL13 in skin 
lesions [27] and a higher frequency of skin-
homing cutaneous lymphocyte-associated 
antigen positive IL4 and IL13 producing T cells in 
skin blisters [28] further support the hypothesis 
that IL4 and IL13 are essential for BP disease 
pathogenesis. Release of eosinophilic granules 
may help explain the prominent pruritus observed 
in BP but not in other blistering disorders, which 
typically lack eosinophilic infiltration [26]. Pruritus 
without blisters can be the first presentation of BP 
[29]. The efficacy of dupilumab in successfully 
controlling this patient’s pruritus may highlight a 
clinically relevant common Th2 pathway, which 
drives pruritus in both atopic dermatitis and BP. 
To our knowledge, there has been only one report 
of dupilumab for the treatment of BP in the 
literature [30]. This patient was also an elderly 
male with eosinophilic infiltration noted on biopsy 
who experienced substantial reduction in itching  
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after the first injection of dupilumab and 
resolution of blisters within the following weeks 
(Table 1). In the previous report, the patient 
initiated dupilumab therapy after two 
unsuccessful prednisone tapers since his 
screening laboratory results were positive for 
Mycobacterium tuberculosis and hepatitis B core 
antibody. In the case presented here, our patient 
failed to fully respond to the standard treatment 
regimen, but achieved acceptable disease control 
with the addition of dupilumab. This case presents 
a likely clinical scenario in which biologics can be 
used in refractory cases and indicates that 
dupilumab may be effective when multiple other 
therapies have failed. Together, these two cases 
highlight a role for dupilumab in the treatment of 
pruritic disorders such as BP. Larger studies are  
needed to ascertain the efficacy and dosing 
regimen for optimal therapeutic success.  
 
Conclusion 
In summary, dupilumab can ameliorate blistering 
and intractable pruritus in a patient with BP 
refractory to corticosteroids, multiple 
immunosuppressants, and omalizumab. Inhibiting 
the activity of Th2 cytokines, IL4 and IL13, by 
dupilumab is an intriguing therapeutic approach 
for BP, especially when pruritus cannot be 
controlled through conventional therapies. 
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Table 1. Comparison of key features in the currently reported case and a prior case report by Kaye et al. [30]. 
 Kaye et al. 2018, JAMA Derm Current report 
Age 80s 88-91 
Sex Male Male 
Clinical manifestations Itching+blisters Itching+blisters 
Pathology 
Eosinophil- and neutrophil-rich 
subepidermal bullae with 3+ linear 
IgG immunoreactivity along the DEJ 
Spongiosis with focal epidermal and 
subepidermal vesicle formation and 
superficial dermal perivascular 
infiltrate containing eosinophils and 
lymphocytes, with linear IgG and C3 
deposition at the DEJ 
Serology 
Undetectable BP180/BP230 after 3 
months of therapy 
Not measured 
Prior treatments Prednisone taper×2  
Prednisone 
Clobetasol 
Triamcinolone acetonide 
Doxycycline 
Nicotinamide 
Mycophenolate mofetil 
Omalizumab 
Various antihistamines 
Duration of prior treatments Unspecified 2.5 years 
Response to dupilumab 
Itching improved within 1 week 
Blisters resolved within 1 month 
Itching improved within 2 weeks 
Blisters resolved within 7 weeks 
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